# Title

 Food and Drugs. PART 2â€”GENERAL ADMINISTRATIVE RULINGS AND DECISIONS


# ID

 CFR-2018-title21-vol1.Pt. 2


# Structured Analysis Summary

| Type        | Values                                                                                                                        |
|:------------|:------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(150.0, 'USD')]                                                                                                              |
| Constraints | ['before', 'exceeds', 'within', 'less than', 'after', 'at least']                                                             |
| Condition   | ['where', 'unless', 'if', 'when', 'subject to']                                                                               |
| Entities    | ['United States', 'Examination', 'Grain', 'Agriculture', 'Such', 'Food', 'Salmonella', 'North', 'U.S. Public Health Service'] |
| Date        | ['2005-01-01', '2018-03-01', '1968-04-11', '2018-12-01', '1964-12-31']                                                        |


# Structured Analysis With Context

 


## Money

| Money          | Context                                                       |
|:---------------|:--------------------------------------------------------------|
| (150.0, 'USD') | (2) The cost of twice the quantity so estimated exceeds $150. |


## Constraints

| Constraints   | Context                                                                                                              |
|:--------------|:---------------------------------------------------------------------------------------------------------------------|
| within        | hearing or other formal proceeding is being held. within                                                             |
| within        | was received in interstate commerce, or was manufactured within  a Territory.                                        |
| at least      | for analysis under the act, he shall collect at least twice the quantity estimated by him to be                      |
| less than     | article available and reasonably accessible for sampling is less than twice the quantity so estimated, in which case |
| exceeds       | The cost of twice the quantity so estimated exceeds  $150.                                                           |
| after         | which such person or owner is a party. after                                                                         |
| within        | in which the article is adulterated or misbranded within the meaning of the act, or otherwise subject                |
| after         | which such person or owner is a party. after                                                                         |
| within        | in which the article is adulterated or misbranded within the meaning of the act, or otherwise subject                |
| before        | request is not made within a reasonable time before the trial of any case under the act,                             |
| after         | under section 305 of the act, and when, after opportunity for presentation of views following such notice,           |
| after         | under section 305 of the act, and when, after opportunity for presentation of views following such notice,           |
| after         | such treated food seeds to remain on hand after  the planting season has passed.                                     |
| after         | (b) On and  after December 31, 1964, the Food and Drug Administration                                                |
| within        | 1968, the Food and Drug Administration declared adulterated within the meaning of section 402(a) of the Federal      |
| within        | Food and Drug Administration will regard as adulterated within the meaning of section 402(a) of the act              |
| after         | the criteria in paragraph (f) of this section after  consultation with a relevant advisory committee(s) and          |
| after         | the criteria in paragraph (f) of this section after  consultation with a relevant advisory committee(s) and          |
| after         | the criteria in paragraph (f) of this section after  consultation with a relevant advisory committee(s) and          |
| at least      | (g)(3)(iii), and (g)(3)(iv) of this section are met. at least                                                        |
| at least      | (g)(3)(iii), and (g)(3)(iv) of this section are met. at least                                                        |


## Condition

| Condition   | Context                                                                                                                     |
|:------------|:----------------------------------------------------------------------------------------------------------------------------|
| when        | to the public health is considered to exist when the evidence is sufficient to show that a                                  |
| when        | interstate commerce, or was manufactured within a Territory. when                                                           |
| if          | sample shall be designated as an official sample if records or other evidence is obtained by him                            |
| when        | as much as is available and reasonably accessible. when                                                                     |
| if          | agent, and such article bears no label or, if it bears a label, no person is named                                          |
| if          | results, to be adequate to establish the respects, if any, in which the article is adulterated or                           |
| subject to  | within the meaning of the act, or otherwise subject to the prohibitions of the act, and has reserved                        |
| if          | results, to be adequate to establish the respects, if any, in which the article is adulterated or                           |
| when        | not exercised his right under such paragraph (c). when                                                                      |
| subject to  | The operation of this paragraph shall be  subject to the exceptions, terms, and conditions prescribed in paragraph          |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| if          | sample; (5) Any official sample or part thereof if the article is perishable; (6) Any official sample                       |
| when        | is authorized to destroy: (1) Any official sample when it determines that no analysis of such sample                        |
| when        | Official Analytical Chemists&#8221;), which are incorporated by reference, when  available and applicable.                  |
| if          | Such treated seed,  if  consumed, presents a hazard to humans and livestock.                                                |
| where       | Food and Drug Administration has encountered many cases where such surplus stocks of treated wheat, corn, oats,             |
| where       | at the time crops are delivered, in cases where  the treated seeds have not been so colored.                                |
| unless      | of the Federal Food, Drug, and Cosmetic Act, unless such seeds have been adequately denatured by a                          |
| where       | labeling requirements of the Federal Hazardous Substances Act, where applicable to denatured seeds in packages suitable for |
| subject to  | of determining whether an article containing ammonia is subject to the Federal Caustic Poison Act, the ammonia content      |
| if          | of the ODS under the Clean Air Act if  paragraph (e) of this section spec                                                   |
| where       | topical use on accessible mucous membranes of humans where  a cannula is used for application.                              |
| if          | own initiative or in response to a petition, if  granted.                                                                   |
| if          | of the product does not release cumulatively sign if icant amounts of ODSs into the atmosphere or                           |
| if          | the investigational product does not release cumulatively sign if icant amounts of ODSs into the atmosphere or              |
| if          | own initiative or in response to a petition, if  granted.                                                                   |


## Entities

| Entities                   | Context                                                                                                                                |
|:---------------------------|:---------------------------------------------------------------------------------------------------------------------------------------|
| Food                       | Food  and Drugs.                                                                                                                       |
| Examination                | Examination  and investigation samples.                                                                                                |
| United States              | being imported or offered for import into the United States .                                                                          |
| North                      | Copies are available from the AOAC INTERNATIONAL, 481  North Frederick Ave., suite 500, Gaithersburg, MD 20877, or                     |
| Grain                      | Grain seed treated with poisonous substances; color identification to                                                                  |
| U.S. Public Health Service | Administration, the National Communicable Disease Center of the U.S. Public Health Service , the Consumer and Marketing Service of the |
| Agriculture                | and Marketing Service of the U.S. Department of Agriculture , and by various State public health agencies                              |
| Such                       | Such contamination has been the result of the original                                                                                 |
| Salmonella                 | Salmonella organisms are commonly present on dressed poultry and                                                                       |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-03-01 | Where the method of analysis is not prescribed in a regulation, it is the policy of the Food and Drug Administration in its enforcement programs to utilize the methods of analysis of the AOAC INTERNATIONAL (AOAC) as published in the latest edition (13th Ed., 1980) of their publication &#8220;Official Methods of Analysis of the Association of Official Analytical Chemists,&#8221; and the supplements thereto (&#8220;Changes in Methods&#8221; as published in the March issues of the &#8220;Journal of the Association of Official Analytical Chemists&#8221;), which are incorporated by reference, when available and applicable. |
| 1964-12-31 | (b) On and after December 31, 1964, the Food and Drug Administration will regard as adulterated any interstate shipment of the food seeds wheat, corn, oats, rye, barley, and sorghum bearing a poisonous treatment in excess of a recognized tolerance or treatment for which no tolerance or exemption from tolerance is recognized in regulations promulgated pursuant to section 408 of the Federal Food, Drug, and Cosmetic Act, unless such seeds have been adequately denatured by a suitable color to prevent their subsequent inadvertent use as food for man or feed for animals.                                                       |
| 1968-04-11 | (c) In a policy statement issued April 11, 1968, the Food and Drug Administration declared adulterated within the meaning of section 402(a) of the Federal Food, Drug, and Cosmetic Act shipments of vegetables or other edible food in used crates or containers that may render the contents injurious to health.                                                                                                                                                                                                                                                                                                                               |
| 2018-12-01 | (c) In a policy statement issued April 11, 1968, the Food and Drug Administration declared adulterated within the meaning of section 402(a) of the Federal Food, Drug, and Cosmetic Act shipments of vegetables or other edible food in used crates or containers that may render the contents injurious to health.                                                                                                                                                                                                                                                                                                                               |
| 2005-01-01 | If the petition is to remove an essential use from paragraph (e) of this section, the petitioner must submit compelling evidence of any one of the following criteria:                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (1) The product using an ODS is no longer being marketed; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (2) After January 1, 2005, FDA determines that the product using an ODS no longer meets the criteria in paragraph (f) of this section after consultation with a relevant advisory committee(s) and after an open public meeting; or                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (3) For individual active moieties marketed as ODS products and represented by one new drug application (NDA):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (i) At least one non-ODS product with the same active moiety is marketed with the same route of administration, for the same indication, and with approximately the same level of convenience of use as the ODS product containing that active moiety;                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Supplies and production capacity for the non-ODS product(s) exist or will exist at levels sufficient to meet patient need;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (iii) Adequate U.S. postmarketing use data is available for the non-ODS product(s); and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) Patients who medically required the ODS product are adequately served by the non-ODS product(s) containing that active moiety and other available products; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (4) For individual active moieties marketed as ODS products and represented by two or more NDAs:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (i) At least two non-ODS products that contain the same active moiety are being marketed with the same route of delivery, for the same indication, and with approximately the same level of convenience of use as the ODS products; and                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) The requirements of paragraphs (g)(3)(ii), (g)(3)(iii), and (g)(3)(iv) of this section are met.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |


